third qtr conference call

Balance sheet is pretty terrific for company market cap of $120M:

* $80.1 million in cash

* Receivables of $36.5 million less total liabilities of $24.5 million = $12 million.

So, if somebody wanted to buy Big Russ Inc at today's price they'd get:

1. $92 million in net cash; and

2. Inavir & Relenza royalty stream, Lani Phase 2, Vapendavir Phase 2b and RSV pre-clinic IP for a mere $28 million.

By the way, it looks like Big Russ believes IGLOO has enough recruited for a meaningful result. Lets hope BARDA agree.